AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
🌍 Cross-language spread
PULSE detected this story across 4 language editions of the world's news.
Detected by matching proper nouns and figures that survive translation. Times reflect when each edition's coverage was first indexed.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include AskTraders, Breakingthenews.net, Bloomberg and Seeking Alpha. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 20h ago.
Quick answers
Why is "AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (16)
- AstraZeneca and Bristol-Myers Squibb in talks over potential merger Yahoo Finance · 16h ago
- AstraZeneca Is Said to Have Explored Bristol Myers Merger Bloomberg.com · 18h ago
- AstraZeneca, BMS reportedly in $400B merger talks FirstWord Pharma · 20h ago
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb CNBC · 20h ago
- AstraZeneca Explored Buying Bristol Myers in Potential Mega Merger Bloomberg.com · 20h ago
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger The Guardian · 20h ago
- AstraZeneca said to have explored Bristol Myers merger Fortune · 21h ago
- AstraZeneca plots £300bn tie-up with US rival Yahoo Finance · 21h ago
- AstraZeneca, Bristol Myers are in talks about merger Endpoints News · 22h ago
- AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports Reuters · 22h ago
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports CNBC · 22h ago
- AstraZeneca in Talks to Merge with Bristol Myers Squibb AskTraders · 22h ago
- AstraZeneca, Bristol Myers could strike merger deal Breakingthenews.net · 22h ago
- AstraZeneca, Bristol Myers Squibb Held Talks for Tie-Up, FT Says Bloomberg · 22h ago
- AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE) Seeking Alpha · 22h ago
- AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up Financial Times · 22h ago
Topics
Related trends
Micron, Bristol Myers, Palantir, Circle Internet, SpaceX, and More Stocks That Explain Today’s Market
A series of major movements across the pharmaceutical and technology sectors is driving current market dynamics, centered on potential mergers and high-profile stocks.
AstraZeneca investors baulk at $400 billion Bristol Myers talks
AstraZeneca investors are resisting proposed acquisition talks with Bristol Myers valued at $400 billion.
AstraZeneca Shares Fall on Deal Talks With Bristol-Myers
AstraZeneca shares decline as reports emerge regarding potential multi-billion-dollar merger talks with Bristol-Myers Squibb.
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
GSK is launching a $2.5 billion cost-saving initiative to accelerate its late-stage drug pipeline and relocate its research headquarters.
Earnings live: AstraZeneca stock rises to kick off a busy earnings week
AstraZeneca’s earnings beat lifts its stock as oncology sales buoy growth and offset a rare drug miss.
Bristol Myers says it will build pharma's 'most powerful' AI supercomputer with Nvidia
Bristol Myers Squibb is partnering with Nvidia to construct what it claims will be the most powerful AI supercomputer in the pharmaceutical industry.